Nexstim Plc
NXTMH.HE
NASDAQ Helsinki9.92
EUR
+0.26
- -
Nexstim Plc
NXTMH.HE
(NASDAQ Helsinki)
Recent
price
9.92
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Nexstim Plc (NXTMH.HE), a Finnish medical technology company founded in 2000 and headquartered in Helsinki, develops and commercializes navigated transcranial magnetic stimulation (nTMS) systems with proprietary SmartFocus 3D navigation technology for precise, personalized brain stimulation; its core offerings span the Diagnostics Business, featuring the NBS System 5 (FDA-cleared and CE-marked for presurgical mapping of speech and motor cortices) and the forthcoming NBS 6 diagnostics system (commercial launch planned for 2025), and the Therapy Business, including the NBT system and NBS System 6 (FDA-cleared for major depressive disorder treatment in the US and CE-marked for major depression and chronic neuropathic pain in Europe); over 240 diagnostic systems and 107 therapy-capable systems are installed worldwide across research universities, hospitals, and clinics in the US, Europe, and other regions. Subsidiaries include Nexstim Inc. and Nexstim Investments LLC in the US, and Nexstim Germany GmbH. The company targets neurosurgery, neuromodulation, neuroscience research, and treatments for challenging brain disorders such as major depressive disorder, chronic neuropathic pain, and emerging indications like Alzheimer's disease. In late 2024, Nexstim signed a development and distributorship agreement with Brainlab AG, designating Brainlab as distributor for certain products focused on non-invasive brain mapping solutions while securing up to EUR 5.1 million in equity investment, including an initial EUR 1.1 million share subscription; this partnership supports 2025 sales targets and expands market reach to Brainlab's global hospital network. In January 2025, Nexstim initiated co-development of the SinaptiStim precision neuromodulation system with Sinaptica Therapeutics Inc. for Alzheimer's treatment, integrating NBS 6 hardware with EEG software and planning first investigational system delivery in March 2025 under a potential 10-year exclusive arrangement. Recent expansions include US clinic partnerships via Nexstim Investments LLC (e.g., with RapidRecovery TMS, Dr. Kuluva, and Dr. Nadkarni), a new stock option plan (2025H) for the Board, a change in Certified Advisor to Carnegie Investment Bank AB, and shipment of the first NBS 6 therapy systems; full-year 2024 net sales grew 20.5% to EUR 8.7 million, with Therapy Business up 41.8% and positive EBITDA of EUR 0.3 million.